Acquisition

Samsung Biologics Launches CHF 1.46B Acquisition of PolyPeptide to Scale Peptide Capabilities

Yuvraj — Mon, 20 Jul 2026 13:22:51 +0000

The global biopharmaceutical contract manufacturing sector is undergoing a rapid transition toward complex modalities as drug developers prioritize specialized treatments for metabolic and chronic conditions. In a major move to consolidate its position within the high-growth peptide market, Samsung Biologics has announced an all-cash public tender offer to acquire 100% of PolyPeptide Group AG. Valued […]

The post Samsung Biologics Launches CHF 1.46B Acquisition of PolyPeptide to Scale Peptide Capabilities first appeared on World Pharma Today.

Merck KGaA to Acquire Bio-Techne for $11.3 Billion to Bolster Life Science Division

Yuvraj — Fri, 26 Jun 2026 07:32:09 +0000

The German pharmaceutical group Merck KGaA announced that it has entered into a definitive agreement to purchase the United States-based biotechnology firm Bio-Techne for $11.3 billion. This transaction represents the largest deal for the Darmstadt-based organization in more than a decade, as it seeks to significantly enhance its global life sciences business. Under the terms […]

The post Merck KGaA to Acquire Bio-Techne for $11.3 Billion to Bolster Life Science Division first appeared on World Pharma Today.

AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal

Yuvraj — Wed, 24 Jun 2026 12:58:04 +0000

In a significant expansion of its research and development capabilities, a definitive agreement has been reached where AbbVie acquires Apogee Therapeutics for $10.9 billion. This strategic transaction is centered around the addition of zumilokibart, a highly anticipated IL-13 antibody, to the acquiring company’s expanding pipeline. By bringing this advanced asset in-house, the organization aims to […]

The post AbbVie Acquires Apogee in $10.9 Billion Healthcare Deal first appeared on World Pharma Today.

Sigma Healthcare Pursues Potential Boots Acquisition Deal

Yuvraj — Thu, 11 Jun 2026 13:13:11 +0000

Australia’s Sigma Healthcare has confirmed that it is participating in discussions regarding a possible acquisition of Boots, the UK health and beauty retailer, in a transaction reportedly valued at up to $10 billion. The company acknowledged its interest after reports emerged that it was among several parties considering a bid for the British chain. In […]

The post Sigma Healthcare Pursues Potential Boots Acquisition Deal first appeared on World Pharma Today.

Incyte Expands Haematology Portfolio with Vega Acquisition

Yuvraj — Wed, 10 Jun 2026 12:29:31 +0000

Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction valued at up to $2bn, reinforcing its presence in haematology with the addition of a late-stage treatment candidate for bleeding disorders. Under the terms of the deal, Incyte will pay $1.25bn upfront and could provide up to $750m in additional […]

The post Incyte Expands Haematology Portfolio with Vega Acquisition first appeared on World Pharma Today.

GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition

Yuvraj — Wed, 10 Jun 2026 12:18:54 +0000

GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a tender offer, GSK will seek to purchase Nuvalent shares at $124 each and plans to finance […]

The post GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition first appeared on World Pharma Today.

Firefly Bio Acquisition Strengthens J&J Cancer Pipeline

Yuvraj — Wed, 10 Jun 2026 12:12:40 +0000

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology. The Firefly Bio acquisition is focused on advancing new treatment approaches for solid tumours associated with […]

The post Firefly Bio Acquisition Strengthens J&J Cancer Pipeline first appeared on World Pharma Today.

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position

Yuvraj — Tue, 09 Jun 2026 07:58:55 +0000

GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion. The deal will make Ayumi a wholly owned subsidiary of GNI Group and significantly expands […]

The post GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position first appeared on World Pharma Today.

CordenPharma Seals AmbioPharm Deal to Expand Global Network

Yuvraj — Sat, 30 May 2026 08:25:37 +0000

CordenPharma, a global contract development and manufacturing organization specializing in complex drug modalities, has officially entered into an agreement to acquire AmbioPharm. The AmbioPharm Deal strengthens the company’s manufacturing presence in the United States while adding newly integrated production capabilities in Shanghai, China. The move allows CordenPharma to comprehensively support the growing global demand for […]

The post CordenPharma Seals AmbioPharm Deal to Expand Global Network first appeared on World Pharma Today.

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Yuvraj — Tue, 12 May 2026 08:55:49 +0000

Angelini Pharma has finalized a definitive agreement to acquire Catalyst Pharmaceuticals for an equity value of approximately €3.5bn ($4.1bn). This move marks a strategic entry into the US market for the company, further consolidating its operational focus on brain health and the treatment of complex conditions. The transaction, which has received unanimous approval from the […]

The post Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition first appeared on World Pharma Today.